Loading...
Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy
Raltegravir is the first licensed compound in 2007 of the new integrase inhibitor drug class. At the dose of 400 mg twice daily, raltegravir showed a potent antiviral action in antiretroviral-naïve patients when associated with tenofovir and emtricitabine. Raltegravir was also found to be highly act...
Na minha lista:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2010
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3108740/ https://ncbi.nlm.nih.gov/pubmed/21694899 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IDR.S8673 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|